GSK reports fall in profit over Zantac fallout—but boosts 2031 revenue target to £40 billion due to boom in cancer drug sales
"We expect another year of profitable growth in 2025, and have further improved our long-term outlook," said CEO Walmsley.
"We expect another year of profitable growth in 2025, and have further improved our long-term outlook," said CEO Walmsley. Read More
